1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol
US5395970A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 15, 1993 |
| Grant date | Mar 7, 1995 |
| Priority date | — |
| Expiry date | Dec 15, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S128/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.